drugset / Trial / NCT07056790
Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer
RandomizedSingle-groupOpen-labelDiagnostic
Summary
68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.
Timeline
- Start
- 2025-05-15
- Primary completion
- 2027-02
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | 68Ga-PSMA-CYC | Diagnostic / imaging agent | 111 mbq | — |
| Comparator | 68Ga-PSMA-CYC | Diagnostic / imaging agent | 148 mbq | — |
| Subject | CYC | Unknown | 111 mbq | Intravenous |
| Subject | CYC | Unknown | 148 mbq | Intravenous |